Physician profile
Caleb Kil
NPI 1699319848
$6,390.31
in general payments reported to CMS, 2019-2025
35 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $1,363 · 2023: $1,897 · 2024: $1,273 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,546 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,546.26 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $845.08 | 2022-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $731.69 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $638.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $547.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.70 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $387.36 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $357.47 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $231.83 | 2021-2024 | Verquvo, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.67 | 2022-2025 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.11 | 2022-2025 | Xifaxan |
| Radius Health, INC. | $149.12 | 2021-2025 | Tymlos |
| Genzyme Corporation | $129.65 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.26 | 2022 | |
| Glaxosmithkline, LLC. | $127.15 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Astellas Pharma US INC | $111.22 | 2023 | Myrbetriq |
| Dexcom, INC. | $101.15 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Sanofi Pasteur INC. | $81.89 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $80.40 | 2022-2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $62.25 | 2022-2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $50.50 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $47.04 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $32.75 | 2025 | Symbravo |
| Abiomed | $28.15 | 2025 | |
| Hologic Sales and Service, LLC | $25.33 | 2025 | Aptima |
| Exeltis, USA INC. | $24.35 | 2025 | Slynd |
| Biogen, INC. | $19.47 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.65 | 2024 | Inpefa |
| Biohaven Pharmaceuticals, INC. | $17.81 | 2021 | |
| Exact Sciences Corporation | $17.45 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $15.65 | 2022 | |
| Aimmune Therapeutics, INC. | $15.30 | 2025 | Zenpep |
| Alk-Abello, INC | $14.43 | 2023 | Grastek, Odactra, Ragwitek |
| Organon LLC | $8.98 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Kil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.